Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Notch Therapeutics
In Canada, an impressive roster of machine learning companies and institutions highlights the research being conducted there. However, a paucity of VC funding and few experienced C-suite leaders has stunted the commercialization of great ideas.
Private Company Edition: Nine new venture capital mega-rounds include Insilico’s series C, $250m from Blackstone for a CAR-T therapy spinout from Intellia and a $210m series B round for Umoja.
With nearly 3,500 therapies in development globally, and almost $480m in start-up financing in Q1 of 2021 alone, the cell, gene and RNA therapy area is seeing a sharp rise in development and attention.
Private Company Edition: New capital for health care and life science innovations include a fund for royalty deals, additional anti-infective funding, early-stage money and public health-focused cash. Also, Day One reveals a $130m series B venture round and Notch closes an $85m series A round.
- Gene Therapy, Cell Therapy
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.